Chiron Corporation

Xoma (US) LLC

Baxter International Inc.

Baxter Healthcare Sa

Ammax Bio, Inc.

Other

Medicinova, Inc.

Avigen, Inc.

University of Colorado

Novartis Vaccines & Diagnostics, Gmbh

Musc Foundation for Research Development

Baxalta Gmbh

G.d. Searle LLC

Dartmouth College

Central Laboratory of the Netherlands Red Cross Blood Transfusion Service

Kirk William Johnson

Toshihiko Takeuchi

Rustum S Boyce

Daniel H Bedinger

Chung-Chiang Hsu

Laman Alani

Hassan Issafras

John M Nuss

Robert F Halenbeck

Savithri Ramurthy

David B Ring

Keith Bruce Pfister

Allan S Wagman

Stephen David Harrison

Bao-lu Chen

Glenn J Dorin

Amer M Mirza

Lynn Seely

Gary V Johnson

Mark E Gustafson

Hassan Madani

Gary S Bild

Michael Tsang

Agnes Choppin Holmes

Gregory L Pattison

Bo H Arve

Paul A Renhowe

Federico C A Gaeta

Michael Huang

Ou Li

Kiranjit Kaur Ahluwalia

Matthew I Gross

Manoj C Desai

Dane A Goff

Sharadha Subramanian

Maninder S Hora

Marina Roell

Abla A Creasey

Barry Haskell Levine

Lucien Adrianus Aarden

Linda May Rothblum Watkins

Xiaohui A Zhou

Mark Rubinstein

Rajsharan K Rana

Raphael D Levy

Patrick N Shaklee

Llewelyn Lao

Sean P Brown

Maninder S Hoba

Robyn Cotter

Aihua Zhu

Rachel A Hunt

Jennifer Bahr-Davidson

Kristin Camfield Lind

Lauren Schwimmer

Hoa Giang

Srinivasa Prasad

Paul Rubin

Daniel T Chu

Kazuko Matsuda

David C Myles

David Duhl

Zhi-Jie Ni

John Corbin

Yuichi Iwaki

Raymond A Chavez

Jennifer Shumilla

Ira Goldfine

Thomas L Ciardelli

Rajneesh Nath

Effie Tozzo

Rejsharan K Bana

Sharmila Vijay

Lance Sultzbaugh

Raisharan K Rana

Linda Watkins

Mark Hutchinson

The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.

Extended local release of anti-CSFR1 antibodies

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

High concentration formulations of anti-CSF1 and anti-CSF1R antibodies

The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors

The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration.

Methods for fucoidan purification from seaweed extracts

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Methods for treating bleeding disorders using sulfated polysaccharides

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Methods for fucoidan purification from sea weed extracts

Growing community of inventors

Moraga, CA, United States of America

Kirk William Johnson